Overview

Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML)

Status:
Not yet recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to compare the efficacy of magrolimab + venetoclax + azacitidine versus placebo + venetoclax + azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Azacitidine
Magrolimab
Venetoclax